T3D Therapeutics Overview
- Founded
-
2013

- Status
-
Private
- Employees
-
14

- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$6M
- Investors
-
4
T3D Therapeutics General Information
Description
Developer of a novel drug therapy designed to offer a transformational approach that can stop or reverse the course of Alzheimer's disease. The company's drug is an orally-delivered once-a-day medicine that targets both the brain 'starvation' and neurodegeneration of Alzheimer's disease and helps in treating multiple manifestations of the disease, enabling Alzheimer's patients to have access to drugs that improve memory, motor function, and cognition.
Contact Information
Website
www.t3dtherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Post Office Box 13628
- 68 T.W. Alexander Drive, Research Triangle Park
- Durham, NC 27709
- United States
+1 (919) 000-0000
T3D Therapeutics Timeline
T3D Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
13. Later Stage VC (Series C) | 03-Sep-2022 | $6M | 000.00 | 0000 | Completed | Clinical Trials - Phase 2 |
12. Grant | 15-Sep-2020 | 00000 | 000.00 | Completed | Clinical Trials - General | |
11. Grant | 01-Aug-2020 | 000 | 000.00 | Completed | Clinical Trials - General | |
10. Later Stage VC (Series B) | 04-Nov-2019 | 0000 | 000.00 | Completed | Clinical Trials - General | |
9. Grant | 20-May-2019 | 000 | 000.00 | Completed | Clinical Trials - General | |
8. Grant | 01-May-2019 | 00.000 | 000.00 | Completed | Clinical Trials - General | |
7. Later Stage VC (Series B) | 10-Mar-2018 | 000 | 000.00 | 0000 | Completed | Clinical Trials - General |
6. Early Stage VC (Series A3) | 11-Mar-2016 | 00.000 | 00.000 | 0000 | Completed | Clinical Trials - General |
5. Grant | 24-Mar-2015 | $1.91M | $1.4M | Completed | Clinical Trials - General | |
4. Debt - General | 31-Jul-2014 | $250K | $1.4M | Completed | Startup |
T3D Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series C | 0,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 0.000 |
Series B | 0,000,000 | 00.000000 | 00 | |||||
Series A3 | 0,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 0.000 |
Series A2 | 482,332 | $0.001000 | 6% | $1.5 | $1.5 | 1x | $1.5 | 2.88% |
Series A1 | 404,628 | $0.001000 | 6% | $1.08 | $1.08 | 1x | $1.08 | 2.42% |
T3D Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of a novel drug therapy designed to offer a transformational approach that can stop or reverse the course of A
Drug Discovery
Durham, NC
14
As of 2022
000.00
000
0000-00-00
00000000000
000.00
T3D Therapeutics Competitors (35)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
NeuroNascent | Venture Capital-Backed | Clarksville, MD | 0 | 00.000 | 00000000000 | |
000 000000 | Venture Capital-Backed | Boston, MA | 0 | 000.00 | 000000000000 | 000.00 |
000000000 | Venture Capital-Backed | New York, NY | 00 | 00000 | 00000000000 | 00000 |
0000000 | Venture Capital-Backed | Singapore, Singapore | 00 | 00000 | 00000000000 | 00000 |
0000000 0000000000 | Venture Capital-Backed | South San Francisco, CA | 00 | 00000 | 00000000000 | 00000 |
T3D Therapeutics Patents
T3D Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210369680-A1 | Methods of treating diseases and disorders resulting from beta coronavirus infection | Pending | 29-Apr-2020 | 0000000000 | 0 |
US-20180153859-A1 | Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype | Inactive | 02-Dec-2016 | 0000000000 | |
EP-3548023-A1 | Methods of dose administration for treating or preventing cognitive impairment using indane acetic acid derivatives | Inactive | 02-Dec-2016 | 0000000000 | |
EP-3548023-A4 | Methods of dose administration for treating or preventing cognitive impairment using indane acetic acid derivatives | Inactive | 02-Dec-2016 | 0000000000 | 0 |
US-20180153860-A1 | Methods of dose administration for treating or preventing cognitive impairment using indane acetic acid derivatives | Inactive | 02-Dec-2016 | A61K31/421 | 0 |
T3D Therapeutics Executive Team (4)
T3D Therapeutics Board Members (7)
Name | Representing | Role | Since |
---|---|---|---|
Barry Buzogany JD | Self | Consultant & Board Member | 000 0000 |
Charles Lineberry Ph.D | Self | Board Member | 000 0000 |
David Keim | Self | Board Member | 000 0000 |
Donald Parker | Self | Board Member | 000 0000 |
John Didsbury Ph.D | T3D Therapeutics | Founder, Chairman, President & Co-Chief Executive Officer | 000 0000 |
T3D Therapeutics Signals
T3D Therapeutics Investors (4)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Alzheimers Association | Corporation | 000 0000 | 000000 0 | ||
National Institute On Aging | Government | Minority | 000 0000 | 000000 0 | |
National Institutes of Health | Government | 000 0000 | 000000 0 | ||
U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 |